Xoma's XomaZyme-CD5 Plus
Executive Summary
For the treatment of acute graft-versus-host disease (GvHD) is expected to be reviewed by FDA's Biological Response Modifiers Advisory Committee at its June 10 meeting. Xoma filed a PLA for the orphan drug in December 1988.